NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas (2027.V1)
Applicable scope: Thymoma (types A, AB, B1, B2, B3), thymic carcinoma, thymic neuroendocrine tumors (TNETs, including thymic carcinoid, large‑cell neuroendocrine carcinoma, small‑cell carcinoma of thymus). This guideline excludes thymic cysts, thymolipoma, thymic hyperplasia, germ cell tumors, lymphoma, and metastatic malignancies to the mediastinum. Core principle: Multidisciplinary team (thoracic surgery, radiation oncology, medical oncology, radiology, pathology) evaluation is strongly recommended for all patients. Masaoka‑Koga staging is adopted for thymoma; thymic carcinoma uses AJCC/UICC TNM staging. WHO histologic classification is mandatory for risk stratification.
Preface
Thymic epithelial tumors (TETs) are rare anterior mediastinal neoplasms with distinct biological behaviors. Thymomas are generally indolent and associated with paraneoplastic syndromes (most commonly myasthenia gravis). Thymic carcinomas are aggressive, high‑grade malignancies with high rates of local invasion and distant metastasis. Thymic neuroendocrine tumors form a separate subgroup with unique management. This 2027.V1 update incorporates recent data on immune checkpoint inhibitors, targeted therapy, stereotactic radiotherapy, and refined criteria for preoperative biopsy.
1. Initial Diagnostic Workup
1.1 Baseline assessment
-
History and physical examination: Screen for myasthenia gravis, pure red cell aplasia, hypogammaglobulinemia (Good syndrome), other autoimmune or paraneoplastic manifestations.
-
Laboratory: CBC, comprehensive metabolic panel, acetylcholine receptor antibody (AChR Ab), muscle‑specific kinase (MuSK) antibody, LDH.
-
Imaging:
-
Contrast‑enhanced chest CT (chest with upper abdomen): first‑line; evaluate tumor size, mediastinal fat invasion, pericardium, great vessel, pleural/pericardial seeding, liver/adrenal metastases.
-
MRI: optional for evaluation of vascular invasion, brachiocephalic vein, superior vena cava, spinal canal involvement.
-
¹⁸F‑FDG PET‑CT: not routine for thymoma. Recommended for suspected thymic carcinoma, high‑grade TNET, distant metastasis, or indeterminate metastatic lesions.
-
Biopsy:
-
If surgical resection is planned and the lesion is clearly resectable: upfront surgery without preoperative biopsy is acceptable.
-
Biopsy is mandatory for locally advanced, unresectable, or metastatic disease, or when lymphoma/germ cell tumor cannot be excluded.
-
Preferred approach: CT‑guided core needle biopsy; fine‑needle aspiration alone is insufficient for WHO subtyping.
-
Transpleural biopsy should be avoided when possible to prevent pleural seeding.
-
Cardiac and pulmonary function testing before surgical or radiotherapy planning.
-
Genetic/biomarker testing:
-
All advanced/metastatic thymic carcinoma: PD‑L1 (CPS/TPS), MSI‑H/dMMR, NGS panel (including KIT, EGFR, MET, HER2, NTRK, TMB).
-
Thymoma: routine NGS is not recommended outside clinical trials.
-
Thymic neuroendocrine tumors: somatostatin receptor imaging (DOTATATE‑PET/CT) is recommended.
2. Staging Systems
2.1 Thymoma: Masaoka‑Koga staging
-
Stage I: Macroscopically completely encapsulated; no capsular invasion
-
Stage IIA: Microscopic capsular invasion
-
Stage IIB: Macroscopic invasion into perithymic fat
-
Stage III: Invasion into adjacent organs (pericardium, great vessels, lung)
-
Stage IVA: Pleural or pericardial dissemination
-
Stage IVB: Distant hematogenous metastasis
2.2 Thymic carcinoma and thymic neuroendocrine tumors: AJCC 8th TNM staging
NCCN note: Thymic carcinoma has higher propensity for nodal and distant spread than thymoma; lymph node evaluation is more important for carcinoma.
3. Treatment for Localized Thymoma (Masaoka‑Koga I–III)
3.1 Stage I thymoma
-
Gross total resection (GTR) is standard.
-
Adjuvant radiotherapy: not recommended routinely. Observation is preferred.
-
Adjuvant radiation may be considered selectively for close surgical margins in high‑risk B2/B3 subtypes, MDT discussion required.
3.2 Stage II thymoma
-
GTR is primary.
-
Observation is acceptable for IIA.
-
For IIB, B2/B3 histology, close or positive margins: adjuvant radiotherapy is an option.
-
Adjuvant chemotherapy is not routine for completely resected stage II thymoma.
3.3 Stage III thymoma (locally invasive, resectable)
-
Upfront GTR if feasible; en bloc resection of involved lung, pericardium, phrenic nerve.
-
If borderline resectable: neoadjuvant chemotherapy (CAP: cyclophosphamide, doxorubicin, cisplatin preferred) ± radiotherapy, then re‑evaluation for surgery.
-
After GTR: adjuvant radiotherapy is recommended for B2/B3, positive/close margins.
-
Subtotal resection (R1/R2): adjuvant chemoradiotherapy.
3.4 Unresectable locally advanced thymoma
-
Definitive concurrent chemoradiotherapy (CAP backbone) or induction chemotherapy followed by radiotherapy.
-
Surgery reassessment after response.
4. Stage IVA Thymoma (pleural/pericardial implants)
-
If limited, resectable pleural/pericardial nodules: surgical cytoreduction (thymectomy + resection of all visible implants) + adjuvant radiotherapy/chemotherapy.
-
Diffuse pleural disease: systemic chemotherapy ± pleural-directed radiotherapy; repeated resection for oligopleural recurrence may be considered.
-
Intrapleural therapies are investigational, only within trials.
5. Thymic Carcinoma (localized / locally advanced / metastatic)
Thymic carcinoma behaves more aggressively than thymoma.
-
Resectable localized thymic carcinoma: GTR + adjuvant radiotherapy; adjuvant chemotherapy may be added for high‑risk features.
-
Borderline resectable locally advanced: neoadjuvant chemotherapy (CAP, or carboplatin + paclitaxel) followed by surgery and adjuvant radiation.
-
Unresectable non‑metastatic: definitive chemoradiation.
-
Metastatic thymic carcinoma: systemic therapy as primary treatment; palliative radiotherapy for symptomatic lesions.
6. Thymic Neuroendocrine Tumors (TNETs)
-
Low/intermediate grade (typical/atypical carcinoid): Surgery is mainstay; DOTATATE‑PET/CT for staging. Somatostatin analogs for progressive, somatostatin receptor‑positive metastatic disease.
-
High‑grade TNET (large‑cell, small‑cell): Platinum‑etoposide chemotherapy backbone, similar to extrapulmonary neuroendocrine carcinoma.
-
Routine lymph node dissection is recommended for TNET.
7. Systemic Therapy Regimens for Advanced / Metastatic TETs
First‑line
-
Thymoma: CAP (cyclophosphamide, doxorubicin, cisplatin) is preferred; alternative: carboplatin + paclitaxel.
-
Thymic carcinoma: Carboplatin + paclitaxel is widely used; CAP is another option.
-
TNET, somatostatin receptor positive: somatostatin analogs (octreotide LAR, lanreotide) for low‑grade progressive disease.
-
High‑grade TNET: cisplatin/carboplatin + etoposide.
Second‑line and subsequent therapy
-
Thymoma: Pemetrexed, gemcitabine, paclitaxel, docetaxel.
-
Thymic carcinoma: Lenvatinib, sunitinib, pembrolizumab (PD‑L1 positive; caution for autoimmune toxicity, especially myasthenia), trabectedin.
-
NTRK fusion positive: larotrectinib / entrectinib.
-
KIT mutation positive: tyrosine kinase inhibitors may be considered.
Important safety warning: Immune checkpoint inhibitors carry substantial risk of triggering or worsening myasthenia gravis and other autoimmune adverse events in thymoma patients; close neurologic monitoring is mandatory.
8. Radiotherapy Principles
-
IMRT / VMAT / IGRT is preferred to reduce dose to heart, lungs, spinal cord, esophagus.
-
Target volume: tumor bed + prior gross disease; elective nodal irradiation is not routine for thymoma.
-
Dose: adjuvant 50–54 Gy; definitive chemoradiation 60–70 Gy.
-
Stereotactic body radiation therapy (SBRT): for isolated oligometastatic or oligorecurrent lesions, or unresectable small local lesions, in specialized centers.
-
Re‑irradiation: high thoracic toxicity risk; only selected oligorecurrence after MDT review.
9. Surveillance
Thymoma
-
Stage I: Chest CT annually for 5 years, then clinical follow‑up.
-
Stage II–IVA: Contrast chest CT every 6 months for first 3 years, then annually for years 4–10.
-
Long‑term monitoring for myasthenia gravis and other autoimmune disease even after resection.
Thymic carcinoma / high‑grade TNET
-
Chest + upper abdomen CT every 3–4 months for 2 years, every 6 months for years 3–5, then annually.
-
PET‑CT only for suspicious recurrence.
10. Special Clinical Scenarios
-
Myasthenia gravis: Optimize acetylcholinesterase inhibitors, steroids, immunosuppression before surgery; perioperative neurology co‑management to reduce myasthenic crisis.
-
Good syndrome (thymoma + hypogammaglobulinemia): Immunoglobulin replacement as needed; infection prophylaxis.
-
Synchronous pleural nodules: Distinguish between stage IVA thymoma seeding vs separate primary lung cancer.
-
Recurrent disease: Oligorecurrence (isolated pleural, lung or mediastinal lesion): reoperation or SBRT; widespread recurrence: systemic therapy.
-
Pregnancy: Multidisciplinary coordination; avoid radiation and anthracyclines during first trimester.
11. 2027.V1 Key Updates
-
Clarified the warning framework for checkpoint inhibitors in thymoma: formal grading of autoimmune toxicity risk, recommendation to avoid PD‑1/PD‑L1 agents in active uncontrolled myasthenia.
-
DOTATATE‑PET/CT is now category 2A for initial staging of all thymic neuroendocrine tumors.
-
Updated neoadjuvant regimen options for borderline resectable thymic carcinoma; carboplatin + paclitaxel elevated in preference.
-
SBRT guidance expanded for oligometastatic/oligorecurrent TETs with normal organ constraints.
-
NGS recommendation refined: NGS not required for thymoma, but mandatory for advanced thymic carcinoma to identify actionable alterations.
-
Pathology note: emphasized separation of B3 thymoma from well‑differentiated thymic carcinoma.
Citation
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas Version 1.2027. Available from NCCN.org.